ZA200306884B - N-phenylarylsulfonamide compound drug containing the compound as active ingredient intermidiate for the compound and processes for producing the same - Google Patents

N-phenylarylsulfonamide compound drug containing the compound as active ingredient intermidiate for the compound and processes for producing the same Download PDF

Info

Publication number
ZA200306884B
ZA200306884B ZA2003/06884A ZA200306884A ZA200306884B ZA 200306884 B ZA200306884 B ZA 200306884B ZA 2003/06884 A ZA2003/06884 A ZA 2003/06884A ZA 200306884 A ZA200306884 A ZA 200306884A ZA 200306884 B ZA200306884 B ZA 200306884B
Authority
ZA
South Africa
Prior art keywords
methyl
amino
isobutyl
thiazolylsulfonyl
furylsulfonyl
Prior art date
Application number
ZA2003/06884A
Other languages
English (en)
Inventor
Hashimoto Shinsuke
Maruyama Takayuki
Kobayashi Kaoru
Naganawa Atsushi
Nakai Yoshihiko
Saitoh Tetsuji
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of ZA200306884B publication Critical patent/ZA200306884B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/70Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/04Drugs for disorders of the urinary system for urolithiasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
ZA2003/06884A 2001-03-12 2003-09-03 N-phenylarylsulfonamide compound drug containing the compound as active ingredient intermidiate for the compound and processes for producing the same ZA200306884B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001068498 2001-03-12
JP2001281569 2001-09-17
JP2002007760 2002-01-16
PCT/JP2002/002245 WO2002072564A1 (en) 2001-03-12 2002-03-11 N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same

Publications (1)

Publication Number Publication Date
ZA200306884B true ZA200306884B (en) 2005-03-30

Family

ID=27346214

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2003/06884A ZA200306884B (en) 2001-03-12 2003-09-03 N-phenylarylsulfonamide compound drug containing the compound as active ingredient intermidiate for the compound and processes for producing the same

Country Status (24)

Country Link
US (3) US7235667B2 (enExample)
EP (2) EP1612208B1 (enExample)
JP (3) JP3555620B2 (enExample)
KR (1) KR100886854B1 (enExample)
CN (1) CN1294126C (enExample)
AT (2) ATE522513T1 (enExample)
AU (1) AU2002238855B2 (enExample)
BR (1) BR0208027A (enExample)
CA (1) CA2439604C (enExample)
CZ (1) CZ304035B6 (enExample)
DE (1) DE60220255T2 (enExample)
DK (2) DK1369419T3 (enExample)
ES (1) ES2286230T3 (enExample)
HU (1) HU230056B1 (enExample)
IL (2) IL157701A0 (enExample)
MX (1) MXPA03008134A (enExample)
NO (1) NO329682B1 (enExample)
NZ (1) NZ528120A (enExample)
PL (1) PL218750B1 (enExample)
PT (2) PT1369419E (enExample)
RU (1) RU2299202C2 (enExample)
TW (1) TWI317359B (enExample)
WO (1) WO2002072564A1 (enExample)
ZA (1) ZA200306884B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003264388A1 (en) * 2002-09-09 2004-03-29 Ono Pharmaceutical Co., Ltd. Process for producing 4-methyl-1,3-thiazol-2-ylsulfonyl halide
DK1603893T3 (da) * 2003-01-29 2008-09-08 Asterand Uk Ltd EP4 -Receptorantagonister
GB0317500D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Treatment of bph
EP1642594A1 (en) * 2003-06-27 2006-04-05 Ono Pharmaceutical Co., Ltd. Remedy for urinary tract diseases
GB0401334D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US20080033018A1 (en) * 2004-07-05 2008-02-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic Agents For Overactive Bladder
JP2008189549A (ja) * 2005-05-12 2008-08-21 Astellas Pharma Inc カルボン酸誘導体またはその塩
JP2009057282A (ja) * 2005-12-19 2009-03-19 Astellas Pharma Inc カルボン酸誘導体又はその塩
TW200817319A (en) * 2006-08-10 2008-04-16 Astellas Pharma Inc Sulfonamide compound or salt thereof
EP2123273B1 (en) 2007-02-16 2013-10-23 ONO Pharmaceutical Co., Ltd. Therapeutic agent for urinary excretion disorder
EP2177512B1 (en) * 2007-08-01 2012-04-18 Taisho Pharmaceutical Co., Ltd. Inhibitor of binding of s1p1
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
EP2305641A4 (en) * 2008-06-23 2012-08-22 Astellas Pharma Inc SULPHONAMIDE COMPOUND OR SALT THEREOF
TW201107309A (en) * 2009-07-27 2011-03-01 Kissei Pharmaceutical Indole derivatives, or the pharmaceutically acceptable salts
JP2013532688A (ja) 2010-07-26 2013-08-19 ブリストル−マイヤーズ スクイブ カンパニー Cyp17阻害剤として有用なスルホンアミド化合物
JP5363636B2 (ja) * 2011-10-21 2013-12-11 ファイザー・リミテッド 新規な塩および医学的使用
US20140039004A1 (en) * 2012-07-31 2014-02-06 Ono Pharmaceutical Co., Ltd. Method of treating of gastroesophageal reflux disease
PT3138633T (pt) * 2014-04-30 2019-02-01 Ind Penalver Sl Cabeça concêntrica programável para aplicação de líquido em tampas de diferentes formatos
EP3375782B1 (en) * 2015-11-13 2020-07-29 Daewoong Pharmaceutical Co., Ltd. Sodium channel blocker
RU2659955C1 (ru) * 2017-10-26 2018-07-04 Галина Ильхамовна Лукина Способ диагностики высоких гастроэзофагеальных рефлюксов

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5748534B2 (enExample) * 1974-03-04 1982-10-16
DE2419923A1 (de) * 1973-04-28 1974-11-28 Fujisawa Pharmaceutical Co Sulfonsaeureester, verfahren zu deren herstellung und verwendung derselben als kondensationsmittel
DE2555048A1 (de) * 1975-12-06 1977-06-30 Pfersee Chem Fab Verfahren und vorrichtung zur herstellung bestaendiger, waessriger emulsionen wasserunloeslicher substanzen
JPS5293469A (en) * 1976-02-02 1977-08-05 Fuji Photo Film Co Ltd Method of curing gelatin
JPH05293469A (ja) 1992-04-17 1993-11-09 Toda Constr Co Ltd 滅菌精製水の製造方法およびその装置
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
WO2000069465A1 (en) * 1999-05-12 2000-11-23 Ono Pharmaceutical Co., Ltd. Anticancer agents containing ep1 antagonists as the active ingredient
KR20020012639A (ko) 1999-07-29 2002-02-19 우에노 도시오 술폰아미드 유도체 및 알로디니아 치료제
CA2440374A1 (en) 2001-03-14 2002-09-19 Takayuki Maruyama A pharmaceutical composition for the treatment of depression comprising the ep1 antagonist as active ingredient

Also Published As

Publication number Publication date
US7629369B2 (en) 2009-12-08
JP2004149545A (ja) 2004-05-27
PT1369419E (pt) 2007-08-16
NO329682B1 (no) 2010-11-29
HUP0400155A3 (en) 2007-05-02
DE60220255D1 (de) 2007-07-05
NO20034007D0 (no) 2003-09-10
HUP0400155A2 (hu) 2004-08-30
ATE522513T1 (de) 2011-09-15
DE60220255T2 (de) 2008-01-17
US20100041708A1 (en) 2010-02-18
ATE362924T1 (de) 2007-06-15
NO20034007L (no) 2003-11-12
NZ528120A (en) 2006-05-26
CZ304035B6 (cs) 2013-08-28
DK1612208T3 (da) 2011-12-12
EP1612208B1 (en) 2011-08-31
CZ20032452A3 (cs) 2003-11-12
PL365100A1 (en) 2004-12-27
RU2299202C2 (ru) 2007-05-20
CN1294126C (zh) 2007-01-10
JP4432051B2 (ja) 2010-03-17
KR20030082978A (ko) 2003-10-23
EP1369419A1 (en) 2003-12-10
CA2439604C (en) 2012-05-01
JP2006028193A (ja) 2006-02-02
PL218750B1 (pl) 2015-01-30
IL157701A0 (en) 2004-03-28
US8088802B2 (en) 2012-01-03
AU2002238855B2 (en) 2007-12-06
TWI317359B (en) 2009-11-21
US20050124672A1 (en) 2005-06-09
MXPA03008134A (es) 2004-03-10
IL157701A (en) 2010-06-30
BR0208027A (pt) 2004-12-28
WO2002072564A1 (en) 2002-09-19
EP1612208A3 (en) 2006-12-06
KR100886854B1 (ko) 2009-03-05
JPWO2002072564A1 (ja) 2004-07-02
PT1612208E (pt) 2011-10-12
JP3741120B2 (ja) 2006-02-01
RU2003127677A (ru) 2005-03-27
CN1509278A (zh) 2004-06-30
US7235667B2 (en) 2007-06-26
HU230056B1 (hu) 2015-06-29
DK1369419T3 (da) 2007-09-24
US20060030713A1 (en) 2006-02-09
CA2439604A1 (en) 2002-09-19
EP1612208A2 (en) 2006-01-04
EP1369419B1 (en) 2007-05-23
ES2286230T3 (es) 2007-12-01
EP1369419A4 (en) 2005-03-16
JP3555620B2 (ja) 2004-08-18

Similar Documents

Publication Publication Date Title
US9387202B2 (en) Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
TWI424999B (zh) 適合作為傑納斯激酶(janus kinase)抑制劑之氮雜吲哚
JP6942380B2 (ja) 新規イソインドリン誘導体、その医薬組成物および使用
JP4777887B2 (ja) 病気および状態の処置および防止のためのフロロ置換オメガカルボキシアリールジフェニル尿素
US8088802B2 (en) N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation
JP7025781B2 (ja) CCケモカイン受容体9(CCR9)の阻害剤と抗α4β7インテグリン遮断抗体の併用療法
KR20140021509A (ko) C-met 키나아제 억제제 화합물
JP2021523887A (ja) XIIa因子インヒビター
KR20150085053A (ko) 헤테로사이클릭 글루타미나아제 억제제
KR20120107493A (ko) 대사성 질환의 치료를 위한 ppar 절약형 티아졸리딘디온염
MX2011010065A (es) Novedoso derivado de hidroxamato, un metodo de produccion del mismo y una composicion farmaceutica que comprende el mismo.
US20040127533A1 (en) Sulfonamide derivatives
RU2512547C2 (ru) Содержащее конденсированную кольцевую структуру производное и его применение в медицине
JP5243596B2 (ja) Hdl−コレステロール上昇剤としての3−トリフルオロメチル−ピラジン−2−カルボン酸アミド誘導体
TW201623226A (zh) 化合物
CA2677769C (en) Therapeutic agent for urinary excretion disorder
JP5442711B2 (ja) Hdl−コレステロール上昇剤としての2−トリフルオロメチルニコチンアミド誘導体
WO2006071035A1 (en) Novel ([1,3]thiazolo[5,4-b]pyridin-2-yl)-2-carboxamide derivatives
WO2024102455A1 (en) Non-covalent inhibitors of coronavirus main protease
JP7788532B2 (ja) Rxfp1受容体アゴニスト
US20250361243A1 (en) Compounds and Pharmaceutical Compositions Useful for Managing Sickle Cell Disease and Conditions Related Thereto
TW201217376A (en) Use for myocardial infarction of KMUP-3